Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with ASXL1 mutations

References

• Ahmad F, Mohota R, Sanap S, et al. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. Asian Pac J Cancer Prev. 2014;15:1247–1253.
   PubMedGoogle Scholar
• Asif N, Hassan N. Acute myeloid leukemia amongst adults. J Islamabad Med Dental College. 2013;2:58–63.
   Google Scholar
• The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–2074.
   PubMed Web of Science ®Google Scholar
• Shih AH, Abdel-wallab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599–612.
   PubMed Web of Science ®Google Scholar
• Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1. Science. 2009;324:930–935.
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Brecqueville M, Devillier R, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12.
   PubMed Web of Science ®Google Scholar
• Cho YS, Kim EJ, Park UH, et al. Additional sex comb-like 1 (ASXL1) in cooperation with SRC-1 acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem. 2006;281(26):17588–17598.
   PubMed Web of Science ®Google Scholar
• Lee SW, Cho YS, Na JM, et al. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem. 2010;285:18–29.
   PubMed Web of Science ®Google Scholar
• Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97:388–392.
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118:6920–6929.
   PubMed Web of Science ®Google Scholar
• El-Sharkawi D, Ali A, Evans CM, et al. ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification. Leuk Lymph. 2014;55:1326–1331.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Eder C, Jeromin S, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia. 2013;27:82–91.
   PubMed Web of Science ®Google Scholar
• Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010;116:4086–4094.
   PubMed Web of Science ®Google Scholar
• Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118:3803–3810.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649.
   PubMed Web of Science ®Google Scholar
• Nolte F, Hofmann WK. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol. 2008;87:777–795.
   PubMed Web of Science ®Google Scholar
• Shivarov V, Gueorguieva R, Ivanova M, et al. ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia. Leuk Lymph. 2015;56:1881–1883.
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang Y, Chen X, et al. Mutaome analysis including 10 common mutated genes in newly diagnosed acute myeloid leukemia patients. J Leuk Lymph. 2015;24(3):161–164.
   Google Scholar
• Tie R, Zhang T, Fu H, et al. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. PLoS One. 2014;9:e93353.
   PubMed Web of Science ®Google Scholar
• Ostronoff F, Othus M, Ho PA, et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia. 2013;27:238–241.
   PubMed Web of Science ®Google Scholar
• Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the acute leukemia French association. Leukemia. 2012;26:1247–1254.
   PubMed Web of Science ®Google Scholar
• Shivarov V, Gueorguieva R, Stoimenov A, et al. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res. 2013;37:1445–1450.
   PubMed Web of Science ®Google Scholar
• Gaidzik V I, Paschka P, Spath D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a Comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol. 2012;30:1350–1357.
   PubMed Web of Science ®Google Scholar
• Wei JF, Chen GH, Qiu HY, et al. The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients. Zhonghua Xue Ye Xue Za Zhi. 2011;32:304–307.
   PubMedGoogle Scholar
• Liu WJ, Tan XH, Luo XP, et al. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. Leuk Lymphoma. 2014;55(12):2691–2698.
   PubMed Web of Science ®Google Scholar
• Green CL, Koo KK, Hills RK, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients With acute myeloid leukemia: impact of double CEBPA mutations and the Interaction With FLT3 and NPM1 mutations. J Clin Oncol. 2010;28:2739–2747.
   PubMed Web of Science ®Google Scholar